Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1
暂无分享,去创建一个
J. Bradner | F. Tirode | D. Heymann | B. Ory | F. Redini | T. Quillard | F. Lamoureux | J. Amiaud | M. Baud’huin | Camille Jacques | L. Calleja
[1] B. Schäfer,et al. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma , 2015, Oncotarget.
[2] K. S. Hall,et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Charles Y. Lin,et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. , 2015, Molecular cell.
[4] Nathan C. Sheffield,et al. Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1 , 2015, Cell reports.
[5] J. Lieb,et al. What are super-enhancers? , 2014, Nature Genetics.
[6] W. Figg,et al. BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancer , 2014, Cancer biology & therapy.
[7] J. Qi,et al. BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD , 2014, Molecular Cancer Therapeutics.
[8] J. Bradner,et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle , 2014, Nature Communications.
[9] U. Kees,et al. Comparative drug screening in NUT midline carcinoma , 2014, British Journal of Cancer.
[10] R. Beroukhim,et al. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.
[11] Travis J Cohoon,et al. Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[12] S. K. Zaidi,et al. Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells , 2013, Journal of cellular physiology.
[13] V. Notario,et al. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing’s sarcoma , 2013, International journal of oncology.
[14] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[15] David A. Orlando,et al. Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.
[16] T. Triche,et al. FOXM1 Is an Oncogenic Mediator in Ewing Sarcoma , 2013, PloS one.
[17] S. Knapp,et al. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. , 2012, Journal of medicinal chemistry.
[18] Francis Y. Lee,et al. MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions , 2012, Sarcoma.
[19] R. Prinjha,et al. Place your BETs: the therapeutic potential of bromodomains. , 2012, Trends in pharmacological sciences.
[20] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[21] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[22] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[23] Qing-Rong Chen,et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. , 2011, Journal of the National Cancer Institute.
[24] J. Khan,et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. , 2011, Neoplasia.
[25] T. MacDonald,et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. , 2011, The Journal of clinical investigation.
[26] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[27] H. Kovar. Downstream EWS/FLI1 - upstream Ewing's sarcoma , 2010, Genome Medicine.
[28] A. Üren,et al. GLI1 Is a Direct Transcriptional Target of EWS-FLI1 Oncoprotein* , 2009, Journal of Biological Chemistry.
[29] H. Kovar,et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.
[30] E. Lalli,et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells , 2008, Oncogene.
[31] T. Triche,et al. The EWS/FLI1 oncogenic transcription factor deregulates GLI1 , 2008, Oncogene.
[32] Qiang Zhou,et al. Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression , 2007, Molecular and Cellular Biology.
[33] S. Lessnick,et al. NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma , 2006, Molecular Cancer Research.
[34] H. Kovar,et al. Ewing's sarcoma family of tumors: current management. , 2006, The oncologist.
[35] O. Delattre,et al. The orphan nuclear receptor DAX1 is up‐regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors , 2006, International journal of cancer.
[36] Mark E. Davis,et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.
[37] O. Delattre,et al. EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 , 2004, Molecular and Cellular Biology.
[38] R. Janknecht,et al. Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing’s Sarcoma , 2004, Clinical Cancer Research.
[39] Y. Iwamoto,et al. Identification of p21 WAF1/CIP1 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein* , 2003, The Journal of Biological Chemistry.
[40] S. Donaldson,et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.
[41] Akihiro Umezawa,et al. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma , 2003, Oncogene.
[42] K. Yudoh,et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas , 2001, British Journal of Cancer.
[43] O. Delattre,et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression , 2001, Oncogene.
[44] K. Tanaka,et al. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G 1 regulatory genes , 2001, British Journal of Cancer.
[45] R. Ilaria,et al. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation , 2000, Oncogene.
[46] S. Welford,et al. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. , 2000, Cancer research.
[47] P. Sorensen,et al. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein , 1999, Nature Genetics.
[48] K. Tanaka,et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. , 1997, The Journal of clinical investigation.
[49] C. Denny,et al. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis , 1995, Molecular and cellular biology.
[50] M. Roussel,et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma , 1994, Molecular and cellular biology.
[51] C. Denny,et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1 , 1993, Molecular and cellular biology.
[52] G. Thomas,et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.
[53] 永野 昭仁. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A , 2010 .
[54] A. Üren,et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma , 2009 .
[55] R. Arceci. Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients , 2009 .
[56] W. Winkelmann,et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. , 2003, International journal of radiation oncology, biology, physics.
[57] T. Komori. Runx2, A multifunctional transcription factor in skeletal development , 2002, Journal of cellular biochemistry.
[58] J. Ewing. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. , 1972, CA: a cancer journal for clinicians.